These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 39289528)
1. Autoantibodies in COVID-19 and Other Viral Diseases: Molecular, Cellular, and Clinical Perspectives. Chatterjee S; Bhattacharya M; Saxena S; Lee SS; Chakraborty C Rev Med Virol; 2024 Sep; 34(5):e2583. PubMed ID: 39289528 [TBL] [Abstract][Full Text] [Related]
2. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Moody R; Wilson K; Flanagan KL; Jaworowski A; Plebanski M Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445670 [TBL] [Abstract][Full Text] [Related]
3. Unveiling the intricacies of COVID-19: Autoimmunity, multi-organ manifestations and the role of autoantibodies. Ding Z; Wei X; Pan H; Shi H; Shi Y Scand J Immunol; 2024 Feb; 99(2):e13344. PubMed ID: 39007954 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 and autoimmune diseases. Liu Y; Sawalha AH; Lu Q Curr Opin Rheumatol; 2021 Mar; 33(2):155-162. PubMed ID: 33332890 [TBL] [Abstract][Full Text] [Related]
5. Autoimmune complications of COVID-19. Yazdanpanah N; Rezaei N J Med Virol; 2022 Jan; 94(1):54-62. PubMed ID: 34427929 [TBL] [Abstract][Full Text] [Related]
6. Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation. Darmarajan T; Paudel KR; Candasamy M; Chellian J; Madheswaran T; Sakthivel LP; Goh BH; Gupta PK; Jha NK; Devkota HP; Gupta G; Gulati M; Singh SK; Hansbro PM; Oliver BGG; Dua K; Chellappan DK Environ Sci Pollut Res Int; 2022 Aug; 29(36):54072-54087. PubMed ID: 35657545 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 infection as a trigger of autoimmune response. Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235 [TBL] [Abstract][Full Text] [Related]
9. Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19. Parums DV Med Sci Monit; 2021 Sep; 27():e934766. PubMed ID: 34538868 [TBL] [Abstract][Full Text] [Related]
10. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Chang SE; Feng A; Meng W; Apostolidis SA; Mack E; Artandi M; Barman L; Bennett K; Chakraborty S; Chang I; Cheung P; Chinthrajah S; Dhingra S; Do E; Finck A; Gaano A; Geßner R; Giannini HM; Gonzalez J; Greib S; Gündisch M; Hsu AR; Kuo A; Manohar M; Mao R; Neeli I; Neubauer A; Oniyide O; Powell AE; Puri R; Renz H; Schapiro J; Weidenbacher PA; Wittman R; Ahuja N; Chung HR; Jagannathan P; James JA; Kim PS; Meyer NJ; Nadeau KC; Radic M; Robinson WH; Singh U; Wang TT; Wherry EJ; Skevaki C; Luning Prak ET; Utz PJ Nat Commun; 2021 Sep; 12(1):5417. PubMed ID: 34521836 [TBL] [Abstract][Full Text] [Related]